Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 9/20 | 0.54 |
| ▸ | FAAH | O00519 | 5/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | XBP1 | P17861 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14962675 | 0.95 | PTGS1 (0.61) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL12285635 | 0.93 | PTGS1 (0.64) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL14962678 | 0.93 | PTGS1 (0.64) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL11915753 | 0.89 | PTGS1 (0.47) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL18704271 | 0.82 | PTGS1 (0.51) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL22424792 | 0.80 | PTGS1 (0.60) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL14962673 | 0.80 | MGLL (0.59) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL10014802 | 0.79 | MGLL (0.60) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL21305870 | 0.78 | MGLL (0.62) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL21152664 | 0.78 | PTGS1 (0.58) | MGLLFAAHPTGS1PTGS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795239-B2 | Products and methods for monitoring adherence to nucleoside reverse transcriptase inhibitor therapy | ORASURE TECHNOLOGIES, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230158141-A1 | Conjugates of Biomolecule and Use Thereof | YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOG (CN) | 2023-05-25 | — | — | US | disclosed |
| US-11548889-B2 | Emetine auristatin compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220196641-A1 | REAGENTS, METHODS, AND SYSTEMS FOR DETECTING THERAPEUTIC AGENTS TO MONITOR ADHERENCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR METABOLITES | ORASURE TECHNOLIGIES, INC. | 2022-06-23 | — | — | US | disclosed |
| EP-3327027-B9 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER (US) | 2021-07-07 | — | — | EP | disclosed |
| US-20210101900-A1 | EMETINE AURISTATIN COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2021-04-08 | — | — | US | disclosed |
| EP-3327027-B1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-3325497-B1 | QUINSTATIN COMPOUNDS | UNIV ARIZONA STATE (US) | 2020-09-02 | — | — | EP | disclosed |
| US-20200239598-A1 | PRODUCTS AND METHODS FOR MONITORING ADHERENCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR THERAPY | URSURE, INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-10435435-B2 | Quinstatin compounds | THE ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-10-08 | — | — | US | disclosed |
| EP-3327027-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | Pfizer Inc (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-2780039-B9 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-2780039-B1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER (US) | 2017-11-29 | — | — | EP | disclosed |
| US-9249186-B2 | Cytotoxic peptides and antibody drug conjugates thereof | PFIZER INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150307551-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. | 2015-10-29 | — | — | US | disclosed |
| US-9138486-B2 | Cytotoxic peptides and antibody drug conjugates thereof | PFIZER INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140363452-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. | 2014-12-11 | — | — | US | disclosed |
| US-8828401-B2 | Cytotoxic peptides and antibody drug conjugates thereof | PFIZER INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20130129753-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307551-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | NGLY1, CD47, CD81 | MGLL 4717/4885FAAH 4538/4885PTGS1 4781/4885 |
| US-20140363452-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | NGLY1, CD47, CD81 | MGLL 4717/4885FAAH 4538/4885PTGS1 4781/4885 |
| US-11548889-B2 | Emetine auristatin compounds | EML4, AURKB, AURKC | MGLL 3676/4885FAAH 1637/4885PTGS1 3242/4885 |
| US-10435435-B2 | Quinstatin compounds | QTRT1, COQ8A, QPCT | MGLL 1412/4885FAAH 3237/4885PTGS1 2437/4885 |
| US-11795239-B2 | Products and methods for monitoring adherence to nucleoside reverse transcriptase inhibitor therapy | DNTT, POLRMT, SLC29A1 | MGLL 3427/4885FAAH 3206/4885PTGS1 4109/4885 |
| US-20210101900-A1 | EMETINE AURISTATIN COMPOUNDS | EML4, AURKB, AURKC | MGLL 3676/4885FAAH 1637/4885PTGS1 3242/4885 |
| US-20200239598-A1 | PRODUCTS AND METHODS FOR MONITORING ADHERENCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR THERAPY | DNTT, POLRMT, SLC29A1 | MGLL 3427/4885FAAH 3206/4885PTGS1 4109/4885 |
| US-20230158141-A1 | Conjugates of Biomolecule and Use Thereof | CD47, FCGR2A, CD40 | MGLL 2474/4885FAAH 2216/4885PTGS1 1461/4885 |
| US-20130129753-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | NGLY1, CD47, CD81 | MGLL 4717/4885FAAH 4538/4885PTGS1 4781/4885 |
| US-20220196641-A1 | REAGENTS, METHODS, AND SYSTEMS FOR DETECTING THERAPEUTIC AGENTS TO MONITOR ADHERENCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR METABOLITES | DNTT, SLC29A1, SAMHD1 | MGLL 3824/4885FAAH 3779/4885PTGS1 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.